Category Archives: Stem Cell Therapy

Tuloy na ang stem cell therapy ni Annabelle Rama dahil naka-schedule na siyang pumunta sa Germany sa first week ng September.

Kasama ni Annabelle sa Germany trip ang kanyang anak na si Ruffa Gutierrez. Hindi ako sure kung may plano rin si Ruffa na magpa-stem cell therapy dahil walang age limit ang procedure na pinag-uusapan na ngayon sa apat na sulok ng showbiz.

Tinutukso si Annabelle Rama na may kinalaman sa kanyang pagkandidato sa Cebu ang desisyon niya na sumailalim sa stem cell therapy.

Tumawa lang si Bisaya na mukhang seryoso na sa pagkandidato bilang kongresista ng North Cebu sa eleksiyon sa susunod na taon.

Binibiro si Bisaya na magpapa-stem cell therapy siya para kundisyon na kundisyon ang katawan niya habang nangangampanya sa North Cebu.

Ayaw kumpirmahin ni Bisaya ang political plans niya. Hintayin na lamang daw ng mga tao ang kanyang bonggang announcement sa October.

Asawa ni Jose nag-iba ng abogado matapos matalo

How true na iba na raw ang lawyers ni Analyn Manalo kaya tumanggi nang magsalita ang kanyang mga dating abogado?

Si Analyn ang kontrobersiyal na dyowa ni Jose Manalo. Ilang buwan nang nasa news ang mag-asawa dahil sa kanilang paghihiwalay.

News noong weekend na natalo si Analyn sa kaso na isinampa niya laban kay Jose.

See more here:
Bibiyahe sa Germany kasama si Ruffa, Annabelle magpapakondisyon sa kampanya kaya magpapa-stem cell therapy

Public release date: 2-Jul-2012 [ | E-mail | Share ]

Contact: Sarah Jackson press_releases@the-jci.org Journal of Clinical Investigation

In Parkinson's disease, the loss of dopamine-producing cells in the midbrain causes well-characterized motor symptoms. Though embryonic stem cells could potentially be used to replace dopaminergic (DA) neurons in Parkinson's disease patients, such cell therapy options must still overcome technical obstacles before the approach is ready for the clinic. Embryonic stem cell-based transplantation regimens carry a risk of introducing inappropriate cells or even cancer-prone cells. To develop cell purification strategies to minimize these risks, Dr. Lorenza Studer and colleagues at Memorial Sloan Kettering Cancer Center in New York developed three different mouse lines to fluorescently label dopaminergic neurons at early, mid, and late stages of differentiation. Their data suggest that mouse embryonic stem cells induced to the mid stage of neuronal differentiation are best suited for transplantation to replace dopaminergic neurons. Further, their work identified new genes associated with each stage of neuronal differentiation. Their results in the mouse model system help define the differentiation stage and specific attributes of embryonic stem cell-derived, dopamine-generating cells that hold promise for cell therapy applications.

###

TITLE:

Identification of embryonic stem cellderived midbrain dopaminergic neurons for engraftment

AUTHOR CONTACT:

Lorenz Studer

Memorial Sloan Kettering Cancer Center, New York, NY, USA

Phone: 212.639.6126; E-mail: studerl@mskcc.org

Link:
Generating dopamine via cell therapy for Parkinson's disease

MOBILE, Alabama -- The Baldwin County doctor that treated former Alabama football players with adult stem cells also has treated at least two people diagnosed with amyotrophic lateral sclerosis, also known as Lou Gehrigs disease.

One of the ALS patients, former NFL football player and college coach Frank Orgel, recently underwent a new stem cell reprogramming technique performed by Dr. Jason R. Williams at Precision StemCell in Gulf Shores.

Before the injections, Orgels health had declined. He could not move his left arm or leg. He couldnt walk or stand on his own, he said.

Within a few days of having the stem cell treatment, Orgels constant muscle twitching diminished, said Bob Hubbard, director of stem cell therapy at the practice. Within weeks, he was able to walk in a pool of water and stand unassisted.

I think its helped me, said Orgel, who was a defensive coordinator at Auburn under former head coach Pat Dye. Im walking in the pool and I used to drag my feet. Now my left leg is picking up.

ALS is a progressive neuro-degenerative disease that affects nerve cells in the brain and the spinal cord. The progressive degeneration of the motor neurons in ALS eventually leads to death, according to the ALS Association.

Stem cells, sometimes called the bodys master cells, are precursor cells that develop into blood, bones and organs, according to the U.S. Food and Drug Administration, which regulates their use. Their promise in medicine, according to many scientists and doctors, is that the cells have the potential to help and regenerate other cells.

While Williams treatments are considered investigational, he has said, they meet FDA guidelines because the stem cells are collected from a patients fat tissue and administered back to that patient during the same procedure.

Orgel, 74, said Williams told him it would take between eight months to a year for his nerves to regrow. He is traveling to Gulf Shores from his home in Albany, Ga., this weekend for another stem cell treatment, Orgel said: I need to get to where I can walk.

In recent years, Orgel has gone to Mexico at least three times for different types of treatments, not sanctioned in the U.S. At least once, he said, he had placenta cells injected into his body. That didnt work, Orgel said. I didnt feel any better.

See the article here:
Former Auburn coach getting stem cell treatments for Lou Gehrig's disease

Halfway around the world in India, Sivaprakash Ramalingam had heard of Johns Hopkins researchers using a promising new technique for gene therapy that he hoped to integrate with stem cells to cure diseases.

After getting a doctorate in biochemistry in his native country, he came to Baltimore four years ago to study under the technique's pioneer, Srinivasan Chandrasegaran, at Hopkins' Bloomberg School of Public Health. Ramalingam's research has led him down the path of seeking a cure for sickle cell anemia, a painful, life-shortening blood disorder that afflicts many in his home region in southern India. In the United States, the disease affects 70,000-100,000 people, mostly African-Americans, according to the National Heart Lung and Blood Institute.

"I couldn't have done this type of research in India," said Ramalingam. "I wanted to use this technique with stem cells to treat disease."

Ramalingam's research was given a lift last month by the state. He was one of 17 researchers who was funded by the Maryland Stem Cell Research Commission, a state entity that has doled out roughly $10 million to $12 million a year in taxpayer funds since its founding in 2006.

The program helps keep Maryland competitive in stem cell research when other states have instituted similar ones to lure scientists and biotechnology companies. More than 100 researchers applied for funding from the program, many from Johns Hopkins and the University of Maryland.

"There's definitely a great demand for the awards," said Dan Gincel, the commission's director. "We're trying to figure out how to fund so many researchers."

Gincel said Ramalingam's work is interesting because his approach could have applications beyond sickle cell anemia. It could be used to treat other diseases and, for instance, modify plants and crops to make them resistant to pests.

Ramalingam received a $110,000 award two years ago from the commission to help fund his post-doctoral fellowship; the commission invested more money in his work this year because he was continuing to progress with it, Gincel said.

"The approach can be translated to many other diseases, which is what we want to see with stem cells," said Gincel.

Ramalingam is applying a relatively new technique called zinc finger nuclease, or ZFN, to try to cure sickle cell anemia. With ZFN, Ramalingam is able to target and replace specific, problem-causing sequences of the human genome with healthier genetic material.

See original here:
Researcher hunts for sickle cell anemia cure with gene targeting, stem cells

VANCOUVER -- For the first time ever, University of B.C. scientists have used human embryonic stem cell transplants to reverse Type 1 diabetes in mice with the disease, giving hope to about 300 million people around the world who suffer from the chronic disease.

A 13-member team, whose milestone work is published in the journal Diabetes, shows that after transplantation, the stem cells matured into insulin-secreting, pancreatic beta-cells. The cells automatically sensed blood sugar levels to release the right amount of insulin and a few dozen diabetic mice were gradually weaned off insulin given to them over a period of months.

Insulin is produced by beta-cells to to help the body absorb sugar and use it for energy.

Essentially, the mice were cured of their diabetes by placing the body back in charge of regulated insulin production as it is in healthy, non-diabetics, said lead author Timothy Kieffer.

It took about four to five months for the [stem] cells to become functional in our experiments and the mice were able to maintain good blood glucose levels even when fed a high-glucose diet, said Kieffer, a UBC professor in the department of cellular and physiological sciences.

Type 1 diabetes otherwise known as juvenile diabetes is an autoimmune disease in which a patients immune system kills off insulin-producing cells in the pancreas. About 10 per cent of diabetics are Type 1 and typically, they must inject themselves with insulin or use pumps to control their blood glucose levels.

While pancreatic islet cell transplantation pioneered at the University of Alberta several years ago has been shown to be an effective way of reducing dependence on insulin injections, the treatment is costly and cumbersome as it requires donor cells from cadavers, which are always in short supply. As well, islet cell transplant patients must forever take anti-rejection drugs that can cause organ damage.

In the study methodology, mice were anesthetized and then injected with millions of cells derived from stem cells which were placed under the left kidney area.

Although the research showed that stem cells may one day provide a cure for diabetes, it also revealed hurdles to overcome before agencies like the Food and Drug Administration in the United States or Health Canada can approve the therapy.

For example, some mice developed bone or cartilage in areas where the cells were inserted, an unacceptable side-effect that future experiments must resolve.

View original post here:
Diabetes breakthrough: UBC scientists reverse disease in mice using stem-cell transplants